clofibrate has been researched along with Body Weight in 176 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study analyzed the effects of the chronic administration of clofibrate, a peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, on the development and established hemodynamic, morphologic, metabolic, and renal manifestations of hyperthyroidism in rats." | 7.74 | Clofibrate prevents and reverses the hemodynamic manifestations of hyperthyroidism in rats. ( Cruz, A; Moreno, JM; Osuna, A; Rodríguez-Gómez, I; Soler, A; Vargas, F, 2008) |
| "Some patients with familial hypercholesterolemia (FHC, type II) are highly responsive to the cholesterol-lowering effect of clofibrate, while others are not only resistant to this effect but may even show an increase in plasma beta-lipoproteins." | 7.65 | Pharmacokinetics of clofibrate in familial hypercholesterolemia. ( Boulet, L; Davignon, J; Pichardo, R, 1977) |
| "This study analyzed the effects of the chronic administration of clofibrate, a peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, on the development and established hemodynamic, morphologic, metabolic, and renal manifestations of hyperthyroidism in rats." | 3.74 | Clofibrate prevents and reverses the hemodynamic manifestations of hyperthyroidism in rats. ( Cruz, A; Moreno, JM; Osuna, A; Rodríguez-Gómez, I; Soler, A; Vargas, F, 2008) |
| "All animals were fed HFD but only 2/12 animals were fed HFD plus clofibrate-developed fatty liver." | 3.72 | Ligand-induced expression of peroxisome proliferator-activated receptor alpha and activation of fatty acid oxidation enzymes in fatty liver. ( Akbiyik, F; Bozkaya, H; Cinar, K; Demirpence, E; Haziroglu, R; Ozsullu, T; Tunca, R; Uzunalimoglu, O; Yurdaydin, C, 2004) |
| "Rainbow trout (Salmo gairdneri), average body weight of 450 g, were treated with 15, 25, or 35 mg/kg of ciprofibrate via intraperitoneal injection every other day for 2 to 3 weeks." | 3.68 | Induction of peroxisome proliferation in rainbow trout exposed to ciprofibrate. ( Baldwin, LA; Calabrese, EJ; Kostecki, PT; Yang, JH, 1990) |
| "The effects of administration of phenformin and clofibrate to 32 breast cancer patients who underwent radical mastectomy and suffered from hormonal metabolic disturbances involving a decline in immunologic response were investigated." | 3.66 | Metabolic immunodepression and metabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. ( Berstein, LM; Buslaeva, VP; Dilman, VM; Fedorov, SN; Kondratjev, VB; Nemirovsky, VS; Nikiforov, YF; Ostroumova, MN; Poroshina, TE; Seleznev, IK; Semiglazov, VF; Tsyrlina, EV; Vasilyeva, IA, 1982) |
| "Some patients with familial hypercholesterolemia (FHC, type II) are highly responsive to the cholesterol-lowering effect of clofibrate, while others are not only resistant to this effect but may even show an increase in plasma beta-lipoproteins." | 3.65 | Pharmacokinetics of clofibrate in familial hypercholesterolemia. ( Boulet, L; Davignon, J; Pichardo, R, 1977) |
| "Hens treated with clofibrate also had lower mRNA concentrations of fatty acid synthase, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, and low-density lipoprotein receptor, proteins involved in fatty acid biosynthesis and cholesterol biosynthesis and uptake, than hens fed the control diet (P<0." | 2.73 | Effects of clofibrate treatment in laying hens. ( Brandsch, C; Eder, K; Haase, K; Kluge, H; König, B; Stangl, GI, 2007) |
| " Patients receiving clofibrate and both estrogen dosage groups had the highest incidence of cholecystitis or cholelithiasis." | 2.64 | Gallbladder disease as a side effect of drugs influencing lipid metabolism. Experience in the Coronary Drug Project. ( , 1977) |
| "Hypertriglyceridemia has been recently recognized as a vascular risk factor, based on both clinical and experimental findings." | 2.38 | Pharmacological control of hypertriglyceridemia. ( Franceschini, G; Paoletti, R, 1993) |
| "Clofibrate treatment was shown to concomitantly decrease the liver levels of HNF1α, HNF4α and PCSK9 mRNA, as well as serum PCSK9, TAGs and total cholesterol concentrations in CRF rats." | 1.43 | Up-regulation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations. ( Rutkowski, B; Sucajtys-Szulc, E; Swierczynski, J; Szolkiewicz, M, 2016) |
| "Clofibrate did not increase the frequency of MNed cells in the bone marrow in the 14-day study, whereas a slight increase was observed at the highest dose in the 28-day study." | 1.42 | Repeated dose liver micronucleus assay using clofibrate in young adult rats. ( Fujii, W; Hori, H; Kawasako, K; Takashima, R; Takayanagi, T; Tanaka, Y; Wako, Y, 2015) |
| "Pigs treated with clofibrate had higher relative mRNA concentrations of OCTN2 in liver (3." | 1.35 | Clofibrate treatment up-regulates novel organic cation transporter (OCTN)-2 in tissues of pigs as a model of non-proliferating species. ( Eder, K; Fischer, M; Geissler, S; Hirche, F; Kluge, H; Luci, S; Ringseis, R; Spielmann, J; Wen, G, 2008) |
| "Pigs treated with clofibrate had heavier livers, moderately increased mRNA concentrations of various PPAR-alpha target genes in liver and adipose tissue, a higher concentration of 3-hydroxybutyrate, and markedly lower concentrations of triglycerides and cholesterol in plasma and lipoproteins than control pigs (P < 0." | 1.34 | Clofibrate causes an upregulation of PPAR-{alpha} target genes but does not alter expression of SREBP target genes in liver and adipose tissue of pigs. ( Eder, K; Giemsa, B; Kluge, H; Luci, S, 2007) |
| "Pigs treated with clofibrate had higher hepatic activities of T(3)- and T(4)-UDP glucuronosyltransferases (UGT) and lower concentrations of total and free T(4) and total T(3) in plasma than control pigs (P < 0." | 1.33 | Clofibrate increases hepatic triiodothyronine (T3)- and thyroxine (T4)-glucuronosyltransferase activities and lowers plasma T3 and T4 concentrations in pigs. ( Eder, K; Hirche, F; Kluge, H; Luci, S, 2006) |
| " Analysis of dose-response exposures to DEHP by reverse transcription (RT)-PCR confirm these results and also shows that GRP58 is not altered in kidney or testis." | 1.30 | A glucose-regulated protein, GRP58, is down-regulated in C57B6 mouse liver after diethylhexyl phthalate exposure. ( Gill, SS; Muhlenkamp, CR, 1998) |
| "Clofibrate-treated rats showed typical changes with increases in hepatic PCoA oxidase and CAT activity (5." | 1.30 | Investigation of the potential of conjugated linoleic acid (Cla) to cause peroxisome proliferation in rats. ( Jones, PA; Lea, LJ; Pendlington, RU, 1999) |
| "Incidences of hepatocellular carcinomas were 75% (9/12, P < 0." | 1.30 | Dose-dependent induction of carcinomas and glutathione S-transferase placental form negative eosinophilic foci in the rat liver by di(2-ethylhexyl)phthalate after diethylnitrosamine initiation. ( Hagiwara, A; Hasegawa, R; Imaida, K; Ito, N; Sano, M; Shirai, T; Tamano, S, 1999) |
| "The hypolipidemic drug ethyl chlorophenoxyisobutyrate (clofibrate) is known to induce peroxisome proliferation and to be carcinogenic after long term administration to rats and mice." | 1.29 | Effects of chronic administration of the peroxisome proliferator, clofibrate, on cytosolic acetyl-CoA hydrolase in rat liver. ( Isohashi, F; Nakanishi, Y; Okamoto, K, 1993) |
| "Uracil was administered during weeks 9-11 at a dietary level of 3." | 1.28 | Promoting effect of the peroxisome proliferator, clofibrate, but not di(2-ethylhexyl)phthalate, on urinary bladder carcinogenesis in F344 rats initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. ( Asakawa, E; Fukushima, S; Hagiwara, A; Ogiso, T; Tamano, S, 1990) |
| "Ciprofibrate was fed to female Sprague-Dawley rats at concentrations of 0, 0." | 1.28 | Effect of the peroxisome proliferator ciprofibrate on hepatic DNA synthesis and hepatic composition following partial hepatectomy in rats. ( Chow, CK; Glauert, HP; Srinivasan, SR, 1990) |
| "Clofibrate was more than 10 times less potent than YM-95831 in the hypolipidemic activity." | 1.27 | Aminophenyl ether compound (YM-95831), a new hypolipidemic agent with a high density lipoprotein elevating activity in rats. ( Maeno, H; Nitatori, R; Ohata, I; Sakamoto, N, 1983) |
| " at an overall dosage of 1275 mg/kg, 2-(p-chlorophenoxy)propionic acid (0." | 1.27 | Effect of phenoxy acids on rat liver regeneration. ( Gershbein, LL, 1984) |
| "Clofibrate treatment decreased drastically the activity of serum postheparin lipoprotein lipase of rats fed with fat-free test diet but had no effect on hepatic lipase." | 1.27 | Clofibrate decreases jejunal cholesterol synthesis and activity of postheparin plasma lipoprotein lipase in the rat. ( Kuusi, T; Miettinen, TA; Strandberg, TE; Tilvis, RS, 1983) |
| "Nafenopin was also added to either a high carbohydrate (70% of kilocalories from glucose) or high fat (70% of kilocalories from lard) diet and fed to rats for either 1 or 3 weeks." | 1.27 | The effect of three hypolipidemic drugs on catalase activity and peroxisomal and mitochondrial palmitate oxidation in rat cardiac and skeletal muscle. ( MacDonald, RS; Swan, PB, 1986) |
| "Clofibrate caused an increase in liver weight without affecting body weight." | 1.27 | Alterations in rat serum lipids and apolipoproteins following clofibrate treatment. ( Dashti, N; Ontko, JA, 1983) |
| "Rats treated with clofibrate revealed foci of cellular alteration that were more often basophilic and occurred slightly sooner (wk 42) than those in untreated controls (wk 60)." | 1.27 | Hepatic foci of cellular and enzymatic alteration and nodules in rats treated with clofibrate or diethylnitrosamine followed by phenobarbital: their rate of onset and their reversibility. ( Greaves, P; Irisarri, E; Monro, AM, 1986) |
| "Clofibrate was used as the standard product." | 1.26 | Toxicological studies of plafibride. Part 2: Subacute and subchronic toxicity in rats and chronic toxicity in dogs. ( Bruseghini, L; Sanfeliu, C; Zapatero, J, 1981) |
| "Niceritrol treatment was associated with increased blood glucose, decreased K value, elevated fasting serum insulin and serum insulin at 60 min during IVGTT." | 1.26 | Changes in glucose tolerance and plasma insulin during lipid-lowering treatment with diet, clofibrate and niceritrol. ( Hellsing, K; Lithell, H; Vessby, B, 1982) |
| "Clofibrate treatment also induced an increase of many times in the activities of mitochondrial alpha-GPD and carnitine acyltransferases, the effect increasing with the dose used." | 1.26 | Effect of clofibrate and gemfibrozil on the activities of mitochondrial carnitine acyltransferases in rat liver. Dose--response relations. ( Kähönen, MT; Ylikahri, RH, 1979) |
| "Ciprofibrate was convenient to take and was without subjective side effects." | 1.26 | Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. ( Olsson, AG; Orö, L, 1982) |
| "The pathogenesis of arteriosclerosis is unknown." | 1.26 | [Lipid lowering treatment and regression of arteriosclerosis (author's transl)]. ( Greten, H; Klose, G, 1980) |
| "If the hypercholesterolemia was continued for 18 months, no significant change in the cholesterol ester content in the aorta occurred; in the coronary arteries there was a significant decrease in these older pigs." | 1.26 | Experimental atherosclerosis in hypercholesterolemic mini-pigs. Regression of cholesterol ester accumulation in aorta and coronary arteries after treatment with clofibrate, beta-pyridylcarbinol or a normo-lipidemic diet. ( Jacobsson, L; Lundholm, L, 1982) |
| "Clofibrate treatment resulted in a reduction of plasma cholesterol, hepatic HMG-CoA reductase and cholesterol 7 alpha-hydroxylase activities." | 1.26 | Effect of probucol on cholesterol metabolism in the rat. ( Holets, RJ; Kottke, BA; Li, JR, 1980) |
| "Bezafibrate is a potent lipid-lowering agent of the new generation." | 1.26 | Clinical experience with bezafibrate. ( Hausmann, L; Kaffarnik, H; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980) |
| " No significant differences were seen in the pharmacokinetic parameters observed for antipyrine, a drug which is less than 10% bound to plasms proteins." | 1.25 | Pharmacokinetics of drugs in patients with the nephrotic syndrome. ( Azarnoff, DL; Cohlmia, JB; Gugler, R; Huffman, DH; Shoeman, DW, 1975) |
| " In 6 patients given cholestyramine together with clofibrate, there was no significant alteration in fasting plasma CPIB levels, 24-hour urinary and faecal excretion of CPIB or in the half-life and pool size of the drug." | 1.25 | Lack of effect of cholestyramine on the pharmacokinetics of clofibrate in man. ( Ahrens, EH; Sedaghat, A, 1975) |
| "Nephrotic syndrome was induced by a single i." | 1.25 | Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia. ( Edwards, KD; Schapel, GJ, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 133 (75.57) | 18.7374 |
| 1990's | 29 (16.48) | 18.2507 |
| 2000's | 10 (5.68) | 29.6817 |
| 2010's | 3 (1.70) | 24.3611 |
| 2020's | 1 (0.57) | 2.80 |
| Authors | Studies |
|---|---|
| Baggaley, KH | 1 |
| Fears, R | 1 |
| Hindley, RM | 1 |
| Morgan, B | 1 |
| Murrell, E | 1 |
| Thorne, DE | 1 |
| Wyrick, SD | 2 |
| Hall, IH | 2 |
| Piantadosi, C | 2 |
| Fenske, CR | 1 |
| Ishaq, KS | 1 |
| Bennett, GB | 1 |
| Houlihan, WJ | 1 |
| Mason, RB | 1 |
| Engstrom, RG | 1 |
| Ashton, MJ | 1 |
| Ashford, A | 1 |
| Loveless, AH | 1 |
| Riddell, D | 1 |
| Salmon, J | 1 |
| Stevenson, GV | 1 |
| Xie, YD | 1 |
| Chen, ZZ | 1 |
| Shao, LH | 1 |
| Wang, QT | 1 |
| Li, N | 1 |
| Lu, WF | 1 |
| Xu, YH | 1 |
| Gao, YQ | 1 |
| Guo, LY | 1 |
| Liu, HL | 1 |
| Li, YP | 1 |
| Yang, GD | 1 |
| Bian, XL | 1 |
| Chen, YT | 1 |
| Jenq, CC | 1 |
| Hsu, CK | 1 |
| Yu, YC | 1 |
| Chang, CH | 1 |
| Fan, PC | 1 |
| Pan, HC | 1 |
| Wu, IW | 1 |
| Cherng, WJ | 1 |
| Chen, YC | 1 |
| Takayanagi, T | 1 |
| Takashima, R | 1 |
| Wako, Y | 1 |
| Kawasako, K | 1 |
| Tanaka, Y | 1 |
| Hori, H | 1 |
| Fujii, W | 1 |
| Sucajtys-Szulc, E | 1 |
| Szolkiewicz, M | 1 |
| Swierczynski, J | 1 |
| Rutkowski, B | 1 |
| STRISOWER, EH | 1 |
| STRISOWER, B | 1 |
| Savolainen, K | 1 |
| Kotti, TJ | 1 |
| Schmitz, W | 1 |
| Savolainen, TI | 1 |
| Sormunen, RT | 1 |
| Ilves, M | 1 |
| Vainio, SJ | 1 |
| Conzelmann, E | 1 |
| Hiltunen, JK | 1 |
| Akbiyik, F | 1 |
| Cinar, K | 1 |
| Demirpence, E | 1 |
| Ozsullu, T | 1 |
| Tunca, R | 1 |
| Haziroglu, R | 1 |
| Yurdaydin, C | 1 |
| Uzunalimoglu, O | 1 |
| Bozkaya, H | 1 |
| Luci, S | 3 |
| Kluge, H | 4 |
| Hirche, F | 2 |
| Eder, K | 4 |
| Giemsa, B | 1 |
| König, B | 1 |
| Haase, K | 1 |
| Brandsch, C | 1 |
| Stangl, GI | 1 |
| Rodríguez-Gómez, I | 1 |
| Cruz, A | 1 |
| Moreno, JM | 1 |
| Soler, A | 1 |
| Osuna, A | 1 |
| Vargas, F | 1 |
| Ringseis, R | 1 |
| Spielmann, J | 1 |
| Fischer, M | 2 |
| Geissler, S | 1 |
| Wen, G | 1 |
| Raheja, KL | 1 |
| Lincheer, WG | 1 |
| Cho, C | 1 |
| Numoto, S | 1 |
| Furukawa, K | 2 |
| Furuya, K | 1 |
| Williams, GM | 2 |
| Romics, L | 1 |
| Dashti, N | 1 |
| Ontko, JA | 1 |
| Kunitomo, M | 3 |
| Takaoka, K | 1 |
| Matsumoto, J | 1 |
| Iwai, H | 1 |
| Bando, Y | 1 |
| Fort, FL | 1 |
| Stein, HH | 1 |
| Langenberg, K | 1 |
| Lewkowski, JP | 1 |
| Heyman, IA | 1 |
| Kesterson, JW | 1 |
| Calatayud, JM | 1 |
| Ohata, I | 1 |
| Sakamoto, N | 1 |
| Nitatori, R | 1 |
| Maeno, H | 1 |
| Rao, MS | 1 |
| Lalwani, ND | 1 |
| Watanabe, TK | 1 |
| Reddy, JK | 1 |
| Gershbein, LL | 1 |
| Jacobsson, L | 1 |
| Lundholm, L | 1 |
| Klose, G | 1 |
| Greten, H | 1 |
| Miettinen, TA | 2 |
| Huttunen, JK | 1 |
| Ehnholm, C | 1 |
| Kumlin, T | 1 |
| Mattila, S | 1 |
| Naukkarinen, V | 1 |
| Lang, PD | 2 |
| Vollmar, J | 2 |
| Strandberg, TE | 1 |
| Kuusi, T | 1 |
| Tilvis, RS | 1 |
| Nyitray, M | 1 |
| Szaszovsky, E | 1 |
| Druga, A | 1 |
| Olsson, AG | 1 |
| Orö, L | 1 |
| Pissarek, D | 1 |
| Panzram, G | 1 |
| Lundershausen, R | 1 |
| Adolph, W | 1 |
| Senf, L | 1 |
| Vessby, B | 3 |
| Lithell, H | 3 |
| Hellsing, K | 3 |
| Ostlund-Lindqvist, AM | 1 |
| Gustafsson, IB | 1 |
| Boberg, J | 2 |
| Ledermann, H | 1 |
| Dilman, VM | 1 |
| Berstein, LM | 1 |
| Ostroumova, MN | 1 |
| Fedorov, SN | 1 |
| Poroshina, TE | 1 |
| Tsyrlina, EV | 2 |
| Buslaeva, VP | 1 |
| Semiglazov, VF | 1 |
| Seleznev, IK | 1 |
| Vasilyeva, IA | 1 |
| Kondratjev, VB | 1 |
| Nemirovsky, VS | 1 |
| Nikiforov, YF | 1 |
| Mochizuki, Y | 1 |
| Sawada, N | 1 |
| Krause, BR | 1 |
| Hartman, AD | 1 |
| Wirth, A | 1 |
| Middelhoff, G | 1 |
| Braeuning, C | 1 |
| Schlierf, G | 1 |
| Mizugaki, M | 1 |
| Nishimaki, T | 1 |
| Yamamoto, H | 1 |
| Sagi, M | 1 |
| Yamanaka, H | 1 |
| Vogelberg, KH | 2 |
| Cicmir, I | 1 |
| Heggen, ME | 1 |
| Sterner, W | 2 |
| Chibanguza, G | 1 |
| Metz, G | 1 |
| Zapatero, J | 1 |
| Sanfeliu, C | 1 |
| Bruseghini, L | 1 |
| Stratmann, FW | 1 |
| Holler, HD | 1 |
| Hofmann, H | 1 |
| Schubotz, R | 1 |
| Schneider, J | 1 |
| Hausmann, L | 1 |
| Mühlfellner, G | 1 |
| Mühlfellner, O | 1 |
| Kaffarnik, H | 1 |
| Arteaga, A | 1 |
| Maiz, A | 1 |
| Lathrop, R | 1 |
| Brook, JG | 1 |
| Lavy, A | 1 |
| Aviram, M | 1 |
| Zinder, O | 1 |
| Li, JR | 1 |
| Holets, RJ | 1 |
| Kottke, BA | 1 |
| Barnard, SD | 1 |
| Molello, JA | 1 |
| Caldwell, WJ | 1 |
| Lebeau, JE | 1 |
| Shand, JH | 2 |
| West, DW | 2 |
| Hamdoune, M | 1 |
| Duclos, S | 1 |
| Mounie, J | 1 |
| Santona, L | 1 |
| Lhuguenot, JC | 1 |
| Magdalou, J | 2 |
| Goudonnet, H | 1 |
| Stanko, RT | 1 |
| Sekas, G | 1 |
| Isaacson, IA | 1 |
| Clarke, MR | 1 |
| Billiar, TR | 1 |
| Paul, HS | 1 |
| Nakanishi, Y | 1 |
| Okamoto, K | 1 |
| Isohashi, F | 1 |
| Wysynski, AM | 1 |
| Baldwin, LA | 2 |
| Leonard, DA | 1 |
| Calabrese, EJ | 2 |
| Franceschini, G | 1 |
| Paoletti, R | 1 |
| Yamoto, T | 1 |
| Ohashi, Y | 1 |
| Furukawa, T | 1 |
| Teranishi, M | 1 |
| Manabe, S | 1 |
| Makita, T | 1 |
| Simpson, AE | 1 |
| Brammar, WJ | 1 |
| Pratten, MK | 1 |
| Elcombe, CR | 1 |
| Muhlenkamp, CR | 1 |
| Gill, SS | 1 |
| Kim, DJ | 1 |
| Lee, KK | 1 |
| Hong, JT | 1 |
| Sano, M | 1 |
| Hagiwara, A | 2 |
| Tamano, S | 2 |
| Hasegawa, R | 1 |
| Imaida, K | 1 |
| Ito, N | 2 |
| Shirai, T | 1 |
| Dobashi, K | 1 |
| Asayama, K | 1 |
| Nakane, T | 1 |
| Hayashibe, H | 1 |
| Kodera, K | 1 |
| Uchida, N | 1 |
| Nakazawa, S | 1 |
| Shoda, T | 1 |
| Mitsumori, K | 1 |
| Onodera, H | 1 |
| Toyoda, K | 1 |
| Uneyama, C | 1 |
| Imazawa, T | 1 |
| Hirose, M | 1 |
| Jones, PA | 1 |
| Lea, LJ | 1 |
| Pendlington, RU | 1 |
| Qu, B | 1 |
| Halliwell, B | 1 |
| Ong, CN | 1 |
| Lee, BL | 1 |
| Li, QT | 1 |
| Pugh, G | 1 |
| Isenberg, JS | 1 |
| Kamendulis, LM | 1 |
| Ackley, DC | 1 |
| Clare, LJ | 1 |
| Brown, R | 1 |
| Lington, AW | 1 |
| Smith, JH | 1 |
| Klaunig, JE | 1 |
| Hamano, T | 1 |
| Kobayashi, K | 1 |
| Sakairi, T | 1 |
| Hayashi, M | 1 |
| Mutai, M | 1 |
| Cayen, MN | 1 |
| Dubuc, J | 1 |
| Dvornik, D | 1 |
| Gotoh, M | 2 |
| Griffin, C | 1 |
| Hruban, Z | 3 |
| Rider, AK | 1 |
| Stone, MC | 1 |
| Thorp, JM | 1 |
| Wain, JS | 1 |
| Schwandt, P | 2 |
| Weisweiler, P | 2 |
| Neureuther, G | 1 |
| Wilkening, J | 1 |
| Miyazawa, S | 1 |
| Sakurai, T | 1 |
| Imura, M | 1 |
| Hashimoto, T | 1 |
| Hedstrand, H | 2 |
| Pichardo, R | 1 |
| Boulet, L | 1 |
| Davignon, J | 4 |
| Gianoulakis, C | 2 |
| Passerini, L | 1 |
| Lis, M | 1 |
| Chrétien, M | 2 |
| Koschinsky, T | 2 |
| Gries, FA | 2 |
| Hansen, W | 1 |
| Nijssen, J | 1 |
| Beckmann, R | 1 |
| Luepker, RV | 2 |
| Smith, LK | 2 |
| Rothchild, SS | 2 |
| Gillis, A | 2 |
| Kochman, L | 2 |
| Warbasse, JR | 2 |
| Wallentin, L | 1 |
| Stejskal, R | 1 |
| Itabashi, M | 1 |
| Stanek, J | 1 |
| Ljunghall, S | 1 |
| Falkensammer, C | 1 |
| Singhal, AK | 1 |
| Brill, DR | 1 |
| Schaffner, CP | 1 |
| Nestruck, AC | 1 |
| Kähönen, MT | 1 |
| Ylikahri, RH | 1 |
| Fredj, G | 1 |
| Clenet, M | 1 |
| Cuchet, P | 2 |
| Rousselet, F | 1 |
| Rozé, C | 2 |
| Christiansen, RZ | 1 |
| Norseth, J | 1 |
| Christiansen, N | 1 |
| Kutz, K | 1 |
| Schulte, A | 1 |
| Just, C | 1 |
| Lindstaedt, H | 1 |
| Reiter, B | 1 |
| Gustafson, A | 1 |
| Chhabra, S | 2 |
| Rasheed, BK | 1 |
| Kurup, CK | 3 |
| Magnusson, O | 4 |
| Hayashi, E | 3 |
| Yamada, J | 1 |
| Terada, M | 1 |
| Sato, M | 1 |
| Rees, ED | 1 |
| Hamilton, RD | 1 |
| Kanner, IF | 1 |
| Wasson, S | 1 |
| Hearn, T | 1 |
| Goldberg, AP | 1 |
| Mellon, WS | 1 |
| Witiak, DT | 3 |
| Feller, DR | 3 |
| Souchard, M | 1 |
| Vaille, C | 1 |
| Debray, C | 1 |
| Owen, JS | 1 |
| Billimoria, JD | 1 |
| Markwell, MA | 1 |
| Bieber, LL | 1 |
| Tolbert, NE | 1 |
| Lenhard, P | 1 |
| Wolfram, G | 2 |
| Gugler, R | 1 |
| Shoeman, DW | 1 |
| Huffman, DH | 1 |
| Cohlmia, JB | 1 |
| Azarnoff, DL | 2 |
| Sedaghat, A | 1 |
| Ahrens, EH | 1 |
| Hosokawa, T | 1 |
| Suzuki, K | 1 |
| sawada, M | 1 |
| Ando, K | 1 |
| Schapel, GJ | 1 |
| Edwards, KD | 1 |
| Dil'man, VM | 1 |
| Bershteĭn, LM | 1 |
| Bobrov, IuF | 1 |
| Kovaleva, IG | 1 |
| Bohmer, T | 1 |
| Olsson, U | 1 |
| Garberg, P | 1 |
| Lundgren, B | 1 |
| Andersson, K | 1 |
| Hultenby, K | 1 |
| Bergstrand, A | 1 |
| Eriksson, AM | 1 |
| Högberg, J | 1 |
| DePierre, JW | 1 |
| Watanabe, T | 1 |
| Okawa, S | 1 |
| Itoga, H | 1 |
| Imanaka, T | 1 |
| Suga, T | 1 |
| Shoji, S | 1 |
| Gerbracht, U | 1 |
| Bursch, W | 1 |
| Kraus, P | 1 |
| Putz, B | 1 |
| Reinacher, M | 1 |
| Timmermann-Trosiener, I | 1 |
| Schulte-Hermann, R | 2 |
| Chinje, E | 1 |
| Gibson, GG | 2 |
| Sato, A | 1 |
| Watanabe, K | 1 |
| Fukuzumi, H | 1 |
| Hase, K | 1 |
| Ishida, F | 1 |
| Kamei, T | 1 |
| Schön, HJ | 1 |
| Kremser, K | 1 |
| Prager, C | 1 |
| Kramar, R | 1 |
| Yamaguchi, Y | 1 |
| Yamada, K | 1 |
| Kitagawa, S | 1 |
| Ogiso, T | 1 |
| Asakawa, E | 1 |
| Fukushima, S | 1 |
| Butler, EG | 1 |
| Ichida, T | 1 |
| Maruyama, H | 1 |
| Yang, JH | 1 |
| Kostecki, PT | 1 |
| Srinivasan, SR | 1 |
| Chow, CK | 1 |
| Glauert, HP | 1 |
| Makowska, JM | 1 |
| Anders, C | 1 |
| Goldfarb, PS | 1 |
| Bonner, F | 1 |
| Esbenshade, TA | 1 |
| Kamanna, VS | 1 |
| Newman, HA | 1 |
| Tortorella, V | 1 |
| Mohan, PF | 1 |
| Cleary, MP | 1 |
| Hosokawa, S | 1 |
| Tatematsu, M | 1 |
| Aoki, T | 1 |
| Nakanowatari, J | 1 |
| Igarashi, T | 1 |
| Ujházy, E | 1 |
| Onderová, E | 1 |
| Horáková, M | 1 |
| Bencová, E | 1 |
| Durisová, M | 1 |
| Nosál, R | 1 |
| Balonová, T | 1 |
| Zeljenková, D | 1 |
| Greaves, P | 1 |
| Irisarri, E | 1 |
| Monro, AM | 1 |
| Fournel, S | 1 |
| Pinon, P | 1 |
| Siest, G | 1 |
| Bergseth, S | 1 |
| Christiansen, EN | 1 |
| Bremer, J | 1 |
| Silva, MH | 1 |
| Wixtrom, RN | 1 |
| Hammock, BD | 1 |
| Cibelli, A | 1 |
| Stefanini, S | 1 |
| Ceru, MP | 1 |
| Ohta, F | 1 |
| Gaudemer, F | 1 |
| Lutton, C | 1 |
| Wójcicki, J | 1 |
| Samochowiec, L | 1 |
| Bartłomowicz, B | 1 |
| Hinek, A | 1 |
| Jaworska, M | 1 |
| Gawrońska-Szklarz, B | 1 |
| MacDonald, RS | 1 |
| Swan, PB | 1 |
| Hoogwerf, BJ | 1 |
| Peters, JR | 1 |
| Frantz, ID | 1 |
| Hunninghake, DB | 1 |
| Wilson, DE | 1 |
| Lees, RS | 1 |
| Tomita, T | 2 |
| Yamamura, Y | 1 |
| Nagakura, T | 2 |
| Levy, RI | 1 |
| von Löwis, P | 1 |
| Klemens, UH | 1 |
| Albrink, MJ | 1 |
| Krishnakantha, TP | 1 |
| Schultz, A | 1 |
| Takeshita, R | 1 |
| Dujovne, CA | 1 |
| Hurwitz, A | 1 |
| Kauffman, RE | 1 |
| Ciświcka-Sznajderman, M | 1 |
| Page, W | 1 |
| Vanderveiken, F | 1 |
| Van Melsen, A | 1 |
| Van Melsen, Y | 1 |
| Vastesaeger, M | 1 |
| Muggeo, M | 1 |
| Fedele, D | 1 |
| Tiengo, A | 1 |
| Crepaldi, G | 2 |
| Irsigler, K | 2 |
| Flegel, U | 2 |
| Kühn, P | 1 |
| Schubert, H | 1 |
| Iván, E | 1 |
| Biro, L | 1 |
| Székely, L | 1 |
| Goodman, DS | 1 |
| Noble, RP | 1 |
| Dell, RB | 1 |
| Kritchevsky, D | 1 |
| Tepper, SA | 1 |
| Scott, PJ | 1 |
| Weber, K | 1 |
| Braun-Falco, O | 1 |
| Carter, EA | 1 |
| Isselbacher, KJ | 1 |
| Fellin, R | 1 |
| Briani, G | 1 |
| Bondesson, G | 3 |
| Hedbom, C | 1 |
| Högberg, T | 1 |
| Stjernström, NE | 3 |
| Carlson, LA | 1 |
| Lewis, NJ | 1 |
| Poochikian, GK | 1 |
| Fenderson, RW | 1 |
| Sekowski, I | 1 |
| Mohan, C | 1 |
| Deutsch, S | 1 |
| Benjamin, F | 1 |
| Samuel, P | 1 |
| Slesers, A | 1 |
| Chou, SF | 1 |
| Gronowitz, S | 2 |
| Svenson, R | 1 |
| Dafgård, B | 1 |
| Kim, DN | 1 |
| Lee, KT | 1 |
| Reiner, JM | 1 |
| Thomas, WA | 1 |
| Berkowitz, D | 1 |
| Mertz, DP | 1 |
| Schwoerer, P | 1 |
| Babucke, G | 1 |
| Kannel, WB | 1 |
| Garcia, MJ | 1 |
| McNamara, PM | 1 |
| Pearson, G | 1 |
| Bagdade, JD | 1 |
| Bierman, EL | 1 |
| Porte, D | 1 |
| Thistle, JL | 1 |
| Schoenfield, LJ | 1 |
| Segall, MM | 1 |
| Fosbrooke, AS | 1 |
| Lloyd, JK | 1 |
| Wolff, OH | 1 |
| Page, IH | 1 |
| Lewis, LA | 1 |
| Kokatnur, MG | 1 |
| Malcom, GT | 1 |
| Duncan, CH | 1 |
| Best, MM | 1 |
| Casdorph, HR | 1 |
| Grafnetter, D | 1 |
| Mrhová, O | 1 |
| Janda, J | 1 |
| Aubry, F | 1 |
| Lapierre, YL | 1 |
| Noël, C | 1 |
| Maha, GE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000482] | Phase 3 | 0 participants | Interventional | 1965-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for clofibrate and Body Weight
| Article | Year |
|---|---|
Drug treatment of hyperlipoproteinaemia.
Topics: Body Weight; Clofibrate; Gonadal Steroid Hormones; Humans; Hyperlipoproteinemias; Hypolipidemic Agen | 1983 |
Pharmacological control of hypertriglyceridemia.
Topics: Body Weight; Cardiovascular Diseases; Clofibrate; Exercise; Fatty Acids, Omega-3; Humans; Hypertrigl | 1993 |
Dietary and drug treatment of hyperlipidemia in diabetes.
Topics: Arteriosclerosis; Blood Protein Disorders; Body Weight; Cholestyramine Resin; Clofibrate; Diabetes M | 1974 |
16 trials available for clofibrate and Body Weight
| Article | Year |
|---|---|
Effects of clofibrate treatment in laying hens.
Topics: Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Body Weight; Chickens; Cholesterol | 2007 |
Effect of long-term antihypertensive and hypolipidemic treatment on high density lipoprotein cholesterol and apolipoproteins A-I and A-II.
Topics: Antihypertensive Agents; Apolipoproteins; Body Weight; Cholesterol; Clofibrate; Humans; Hyperlipopro | 1980 |
[Intensified therapy of newly detected maturity onset diabetes].
Topics: Biguanides; Body Weight; Clofibrate; Diabetes Mellitus; Diet, Diabetic; Female; Glucose Tolerance Te | 1980 |
Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar.
Topics: Adult; Apolipoproteins; Bezafibrate; Body Weight; Cholesterol; Cholesterol, LDL; Clofibrate; Clofibr | 1982 |
[The influence of clofibrate on elevated serum lactate levels in diabetic patients treated with biguanides (author's transl)].
Topics: Adult; Biguanides; Body Weight; Clofibrate; Diabetes Mellitus; Enzymes; Female; Humans; Hypoglycemic | 1980 |
[Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)].
Topics: Adult; Aged; Biguanides; Blood Glucose; Body Weight; Buformin; Cholesterol; Clofibrate; Drug Therapy | 1977 |
Management of hypercholesterolemia: evaluation of practical clinical approaches in healthy young adults.
Topics: Adult; Body Weight; Cholesterol; Clofibrate; Dietary Fats; Female; Humans; Hypercholesterolemia; Lip | 1978 |
Gallbladder disease as a side effect of drugs influencing lipid metabolism. Experience in the Coronary Drug Project.
Topics: Adult; Age Factors; Anticholesteremic Agents; Body Height; Body Weight; Cholecystitis; Cholelithiasi | 1977 |
Effects of clofibrate on glucose tolerance, serum insulin, serum lipoproteins and plasma fibrinogen.
Topics: Blood Glucose; Blood Sedimentation; Body Weight; Cholesterol; Clinical Trials as Topic; Clofibrate; | 1977 |
[New drug combination for medical management of hyperlipemia: clinical study].
Topics: Aged; Blood Glucose; Body Weight; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; | 1977 |
Halofenate in the treatment of type II hyperlipoproteinemia. Double blind comparison with clofibrate.
Topics: Adult; Blood Chemical Analysis; Body Weight; Cholesterol; Clinical Trials as Topic; Clofibrate; Fema | 1976 |
[Treatment of primary hyperlipoproteinemia type IIb and IV. Comparison of the lipid lowering effect of phenformin, clofibrate, and a combination of both (author's transl)].
Topics: Adult; Body Weight; Cholesterol; Clofibrate; Drug Therapy, Combination; Female; Humans; Hyperlipidem | 1977 |
Management of type IV hyperlipoproteinemia. Evaluation of practical clinical approaches.
Topics: Adult; Arteriosclerosis; Body Weight; Cholesterol; Clinical Trials as Topic; Clofibrate; Female; Hum | 1976 |
[Treatment of primary hyperlipoproteinaemia types, IIa, IIb, 3 and IV with clofibrate (author's transl)].
Topics: Administration, Oral; Adult; Aged; Alanine Transaminase; Ambulatory Care; Anticoagulants; Aspartate | 1973 |
Colestipol and clofibrate in hypercholesterolemia.
Topics: Adult; Aged; Alkaline Phosphatase; Analysis of Variance; Anticholesteremic Agents; Blood Pressure; B | 1974 |
Effects of a phenolic ether, Su-13437, on serum cholesterol, triglyceride, and transaminase levels of human subjects.
Topics: Adult; Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Body Weigh | 1970 |
157 other studies available for clofibrate and Body Weight
| Article | Year |
|---|---|
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
Topics: Animals; Benzoates; Body Weight; Cholesterol; Fatty Acids; Hypolipidemic Agents; Liver; Male; Organ | 1977 |
Cycloalkanones. 8. Hypocholesterolemic activity of long-chain ketones related to pentadecanone.
Topics: Animals; Anticholesteremic Agents; Body Weight; Castration; Cell Membrane; Cholesterol; DNA; Eating; | 1976 |
Hypocholesterolemic activity of 1,3-bis(substituted phenoxy)-2-propanones.
Topics: Animals; Anticholesteremic Agents; Body Weight; Cholesterol; Depression, Chemical; DNA; Female; Fert | 1976 |
Synthesis and biological evaluation of substituted 2,2'-oxybis(propionic acid) derivatives and related compounds.
Topics: Animals; Body Weight; Cholesterol; Depression, Chemical; Furans; Hypoglycemic Agents; Male; Morpholi | 1976 |
Heterocyclic analogues of chlorcyclizine with potent hypolipidemic activity.
Topics: Animals; Body Weight; Chemical Phenomena; Chemistry; Cholesterol, Dietary; Eating; Hypolipidemic Age | 1984 |
A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
Topics: Animals; Antioxidants; Body Weight; Clofibrate; Dose-Response Relationship, Drug; Hepatocytes; Hypol | 2018 |
Acute kidney disease and acute kidney injury biomarkers in coronary care unit patients.
Topics: Acute Disease; Acute Kidney Injury; Age Factors; Aged; Biomarkers; Body Weight; Clofibrate; Coronary | 2020 |
Repeated dose liver micronucleus assay using clofibrate in young adult rats.
Topics: Administration, Oral; Age Factors; Animals; Body Weight; Bone Marrow; Cell Division; Clofibrate; Com | 2015 |
Up-regulation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations.
Topics: Actins; Animals; Apolipoprotein B-100; Body Weight; Carrier Proteins; Clofibrate; Disease Models, An | 2016 |
THE SEPARATE HYPOLIPOPROTEINEMIC EFFECTS OF DEXTROTHYROXINE AND ETHYL CHLOROPHENOXYISOBUTYRATE.
Topics: Androsterone; Biomedical Research; Blood Chemical Analysis; Blood Proteins; Body Weight; Butyrates; | 1964 |
A mouse model for alpha-methylacyl-CoA racemase deficiency: adjustment of bile acid synthesis and intolerance to dietary methyl-branched lipids.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Bile Acids and Salts; Body Weight; Cholesterol; Cholesterol | 2004 |
Ligand-induced expression of peroxisome proliferator-activated receptor alpha and activation of fatty acid oxidation enzymes in fatty liver.
Topics: Acyl-CoA Dehydrogenase; Acyl-CoA Oxidase; Animals; Antioxidants; Body Weight; Clofibrate; Dietary Fa | 2004 |
Clofibrate increases hepatic triiodothyronine (T3)- and thyroxine (T4)-glucuronosyltransferase activities and lowers plasma T3 and T4 concentrations in pigs.
Topics: Animals; Body Weight; Clofibrate; Gene Expression; Glucuronosyltransferase; Hypolipidemic Agents; Li | 2006 |
Clofibrate causes an upregulation of PPAR-{alpha} target genes but does not alter expression of SREBP target genes in liver and adipose tissue of pigs.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Animals; Anticholesteremic Agents; Apolipoprotein A-I; Apolip | 2007 |
Clofibrate prevents and reverses the hemodynamic manifestations of hyperthyroidism in rats.
Topics: Animals; Blood Pressure; Body Temperature; Body Weight; Clofibrate; Disease Models, Animal; Glucuron | 2008 |
Clofibrate treatment up-regulates novel organic cation transporter (OCTN)-2 in tissues of pigs as a model of non-proliferating species.
Topics: Animals; Betaine; Body Weight; Carnitine; Clofibrate; Eating; Enterocytes; gamma-Butyrobetaine Dioxy | 2008 |
Glycogenolytic and hypolipidemic effect of clofibrate (CPIB) in the hypothyroid chick.
Topics: Animals; Bile; Blood Glucose; Body Weight; Chickens; Clofibrate; Hypothyroidism; Kidney; Lipid Metab | 1980 |
Effects of the hepatocarcinogenic peroxisome-proliferating hypolipidemic agents clofibrate and nafenopin on the rat liver cell membrane enzymes gamma-glutamyltranspeptidase and alkaline phosphatase and on the early stages of liver carcinogenesis.
Topics: 2-Acetylaminofluorene; Alkaline Phosphatase; Animals; Body Weight; Cell Division; Cell Membrane; Clo | 1984 |
Alterations in rat serum lipids and apolipoproteins following clofibrate treatment.
Topics: Animals; Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins B; Apolipoprotei | 1983 |
Consensus conference: Treatment of hypertriglyceridemia.
Topics: Body Weight; Cardiovascular Diseases; Clofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipopro | 1984 |
[Experimental induction of atherosclerosis in guinea pigs fed a cholesterol and vitamin D2-rich diet].
Topics: 4-Aminobenzoic Acid; Animals; Aorta; Arteriosclerosis; Body Weight; Calcium; Cholesterol; Clofibrate | 1983 |
Cetaben versus clofibrate: comparison of toxicity and peroxisome proliferation in rats.
Topics: 4-Aminobenzoic Acid; Aminobenzoates; Animals; Body Weight; Catalase; Clofibrate; Female; Hepatomegal | 1983 |
Favorable effects of the lipid-lowering and platelet antiaggregant Plafibride on the aging process of mice of the C57bl/6J strain.
Topics: Aging; Animal Feed; Animals; Body Weight; Clofibrate; Clofibric Acid; Hypolipidemic Agents; Lipofusc | 1983 |
Aminophenyl ether compound (YM-95831), a new hypolipidemic agent with a high density lipoprotein elevating activity in rats.
Topics: Anilides; Animals; Body Weight; Cholesterol; Cholesterol, HDL; Clofibrate; Diet; Hypolipidemic Agent | 1983 |
Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator.
Topics: Animals; Anisoles; Antioxidants; Body Weight; Butylated Hydroxyanisole; Carcinogens; Clofibrate; Clo | 1984 |
Effect of phenoxy acids on rat liver regeneration.
Topics: Animals; Body Weight; Carboxylic Acids; Clofibrate; Diet; Female; Hepatectomy; Liver; Liver Regenera | 1984 |
Experimental atherosclerosis in hypercholesterolemic mini-pigs. Regression of cholesterol ester accumulation in aorta and coronary arteries after treatment with clofibrate, beta-pyridylcarbinol or a normo-lipidemic diet.
Topics: Animals; Aorta, Abdominal; Aorta, Thoracic; Arteriosclerosis; Body Weight; Cholesterol; Cholesterol | 1982 |
[Lipid lowering treatment and regression of arteriosclerosis (author's transl)].
Topics: Animals; Arteriosclerosis; Body Weight; Cholesterol; Cholesterol, Dietary; Clofibrate; Colestipol; C | 1980 |
[Bezafibrate and delayed action etofibrate in hyperlipidemia].
Topics: Bezafibrate; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Aci | 1983 |
Clofibrate decreases jejunal cholesterol synthesis and activity of postheparin plasma lipoprotein lipase in the rat.
Topics: Animals; Body Weight; Cholesterol; Clofibrate; Diet; Intestinal Mucosa; Intestines; Jejunum; Lipopro | 1983 |
Clofibrate and the development of rats.
Topics: Animals; Body Weight; Clofibrate; Female; Gestational Age; Growth; Liver; Organ Size; Pregnancy; Rat | 1980 |
Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Blood Sedimentation; Body Weight; Cholesterol; Ch | 1982 |
Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters.
Topics: Adult; Apolipoproteins; Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric | 1980 |
Changes in glucose tolerance and plasma insulin during lipid-lowering treatment with diet, clofibrate and niceritrol.
Topics: Aged; Arteriosclerosis; Blood Glucose; Body Weight; Clofibrate; Dietary Carbohydrates; Female; Gluco | 1982 |
Metabolic immunodepression and metabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances.
Topics: Age Factors; Body Weight; Breast Neoplasms; Clofibrate; Female; Hormones; Humans; Hypersensitivity, | 1982 |
Effects of various concentrations of ethyl-alpha-p-chlorophenoxyisobutyrate (clofibrate) on diethylnitrosamine-induced hepatic tumorigenesis in the rat.
Topics: Animals; Body Weight; Clofibrate; Cocarcinogenesis; Diethylnitrosamine; Dose-Response Relationship, | 1982 |
Accumulation of adipocyte cholesterol during hypolipidemic drug treatment in cholesterol-fed rats.
Topics: Adipose Tissue; Animals; Body Weight; Cholesterol; Cholesterol, Dietary; Cholestyramine Resin; Clofi | 1982 |
Studies on the metabolism of unsaturated fatty acids. XI. Alterations in the activities of enoyl-CoA hydratase, 3-hydroxyacyl-CoA epimerase and 2,4-dienyl-CoA reductase in rat liver mitochondria and peroxisomes by clofibrate.
Topics: Animals; Body Weight; Clofibrate; Enoyl-CoA Hydratase; Fatty Acid Desaturases; Hydro-Lyases; Isomera | 1982 |
[Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)].
Topics: Animals; Body Weight; Clofibrate; Diet; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Rats | 1980 |
Toxicological studies of plafibride. Part 2: Subacute and subchronic toxicity in rats and chronic toxicity in dogs.
Topics: Animals; Blood Cell Count; Body Weight; Clofibrate; Clofibric Acid; Dogs; Female; Male; Organ Size; | 1981 |
[Effect of bezafibrate on the carbohydrate metabolism of 17 diabetics with hyperlipidemia].
Topics: Anticholesteremic Agents; Bezafibrate; Body Weight; Carbohydrate Metabolism; Clofibrate; Clofibric A | 1981 |
Clinical experience with bezafibrate.
Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Coronary Disease; | 1980 |
[Hyperlipoproteinemias: experience of out-patient treatment of 112 patients (author's transl)].
Topics: Body Weight; Cholesterol; Cholestyramine Resin; Clofibrate; Humans; Hyperlipoproteinemias; Hypolipid | 1981 |
The concentration of high density lipoprotein in patients with type IV hyperlipoproteinemia and the effect of clofibrate.
Topics: Adult; Body Weight; Cholesterol; Clofibrate; Humans; Hyperlipoproteinemia Type IV; Lipoproteins, HDL | 1980 |
Effect of probucol on cholesterol metabolism in the rat.
Topics: Animals; Body Weight; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Clofibrate; Hydroxymethylglutary | 1980 |
[Comparative study of the effects of probucol, fenofibrate and clofibrate on liver ultrastructure in rats (author's transl)].
Topics: Animals; Body Weight; Clofibrate; Fenofibrate; Hypolipidemic Agents; Lipids; Liver; Microbodies; Mic | 1980 |
The effects of probucol and clofibrate alone and in combination on hepatic cholesterol metabolism in the male rat.
Topics: Animals; Body Weight; Cholesterol; Clofibrate; Cytosol; Lipid Metabolism; Lipids; Liver; Male; Micro | 1995 |
In vitro glucuronidation of peroxisomal proliferators: 2-ethylhexanoic acid enantiomers and their structural analogs.
Topics: Animals; Body Weight; Caproates; Chromatography, High Pressure Liquid; Clofibrate; Glucuronates; Glu | 1995 |
The effects of clofibrate and bezafibrate on cholesterol metabolism in the liver of the male rat.
Topics: Animals; Bezafibrate; Body Weight; Cholesterol; Cholesterol Esters; Clofibrate; Cytosol; Liver; Male | 1994 |
Pyruvate inhibits clofibrate-induced hepatic peroxisomal proliferation and free radical production in rats.
Topics: Animals; Body Weight; Catalase; Clofibrate; Diet; Drug Interactions; Free Radicals; Lipofuscin; Live | 1995 |
Effects of chronic administration of the peroxisome proliferator, clofibrate, on cytosolic acetyl-CoA hydrolase in rat liver.
Topics: Acetyl-CoA Hydrolase; Animals; Biomarkers; Body Weight; Clofibrate; Cytosol; Diet; Enzyme Induction; | 1993 |
Interactive potential of omega-3 fatty acids with clofibrate or DEHP on hepatic peroxisome proliferation in male Wistar rats.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Acyl-CoA Oxidase; Animals; Body Weight; Cell Division; Clofibrate; | 1993 |
Change of the sex-dependent response to clofibrate in F344 rat liver during postnatal development.
Topics: Administration, Oral; Aging; Animals; Body Weight; Cholesterol; Clofibrate; Cytochrome P-450 Enzyme | 1996 |
Translactational induction of CYP4A expression in 10.5-day neonatal rats by the hypolipidemic drug clofibrate.
Topics: Animals; Animals, Newborn; Animals, Suckling; Base Sequence; Blotting, Northern; Blotting, Western; | 1995 |
A glucose-regulated protein, GRP58, is down-regulated in C57B6 mouse liver after diethylhexyl phthalate exposure.
Topics: Animals; Base Sequence; Body Weight; Clofibrate; Diethylhexyl Phthalate; DNA Primers; DNA, Complemen | 1998 |
Differential effects of nongenotoxic and genotoxic carcinogens on the preneoplastic lesions in the rat liver.
Topics: Administration, Oral; Animals; Body Weight; Carcinogens; Cell Count; Clofibrate; Diethylnitrosamine; | 1998 |
Dose-dependent induction of carcinomas and glutathione S-transferase placental form negative eosinophilic foci in the rat liver by di(2-ethylhexyl)phthalate after diethylnitrosamine initiation.
Topics: Adenoma, Liver Cell; Animals; Body Weight; Carcinoma, Hepatocellular; Clofibrate; Cocarcinogenesis; | 1999 |
Effect of peroxisome proliferator on extracellular glutathione peroxidase in rat.
Topics: Aldehydes; Animals; Blotting, Northern; Body Weight; Catalase; Clofibrate; Diethylhexyl Phthalate; E | 1999 |
The relationship between decrease in Cx32 and induction of P450 isozymes in the early phase of clofibrate hepatocarcinogenesis in the rat.
Topics: Animals; Body Weight; Carcinogenicity Tests; Carcinogens; Clofibrate; Connexins; Cytochrome P-450 En | 1999 |
Investigation of the potential of conjugated linoleic acid (Cla) to cause peroxisome proliferation in rats.
Topics: Animals; Body Weight; Carnitine O-Acetyltransferase; Clofibrate; Cytochrome P-450 Enzyme System; Dri | 1999 |
Caloric restriction prevents oxidative damage induced by the carcinogen clofibrate in mouse liver.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acyl-CoA Oxidase; Animals; Body Weight; Carcinogens; Cell Nucleus; Clof | 2000 |
Effects of di-isononyl phthalate, di-2-ethylhexyl phthalate, and clofibrate in cynomolgus monkeys.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Body Weight; Cell Communication; Clofibrate | 2000 |
Peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist, WY-14,643, increased transcription of myosin light chain-2 in cardiomyocytes.
Topics: Animals; Body Weight; Cardiac Myosins; Cell Line; Clofibrate; Diethylhexyl Phthalate; Dose-Response | 2001 |
Effect of clofibrate on lipid metabolism in streptozotocin diabetic rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Diabetes Mellitus; Eat | 1975 |
Effect of citrate and aminotriazole on matrical plates induced in hepatic microbodies.
Topics: Amitrole; Animals; Aspirin; Body Weight; Carboxylic Acids; Catalase; Citrates; Clofibrate; Cycloprop | 1975 |
Should hyperlipoproteinemia be treated in patients with coronary artery disease?
Topics: Adolescent; Adult; Aged; Arteriosclerosis; Body Weight; Cholestyramine Resin; Clofibrate; Coronary D | 1975 |
Experimental and clinical evaluation of two "Atromid-S" analogues in relation to their differential modes of action.
Topics: Animals; Body Weight; Butyrates; Clofenapate; Clofibrate; Diabetes Mellitus; Fatty Acids, Nonesterif | 1975 |
[Effect of clofibrate on glucose tolerance and insulin secretion in patients with endogenous hypertriglyceridemia (author's transl)].
Topics: Administration, Oral; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Glucose; Glucose Toleranc | 1976 |
Effects of ethyl p-chlorophenoxyisobutyrate on carbohydrate and fatty acid metabolism in rat liver.
Topics: Animals; Body Weight; Carbohydrate Metabolism; Cholesterol; Clofibrate; Cytoplasm; Diet; Fatty Acids | 1975 |
Dietary and drug treatment of hyperlipidaemia. A feasibility study in asymptomatic middle-aged men.
Topics: Body Weight; Cholesterol; Clofibrate; Follow-Up Studies; Humans; Hypercholesterolemia; Hyperlipidemi | 1976 |
Pharmacokinetics of clofibrate in familial hypercholesterolemia.
Topics: Adolescent; Adult; Body Weight; Cholesterol; Clofibrate; Dose-Response Relationship, Drug; Drug Resi | 1977 |
Effect of clofibrate treatment on chronic hyperlipidemia induced by an ACTH-producing tumor.
Topics: Adrenocorticotropic Hormone; Animals; Body Weight; Cholesterol; Clofibrate; Growth Hormone; Hyperlip | 1977 |
Lecithin:cholesterol acyl transfer rate and high density lipoproteins in plasma during dietary and clofibrate treatment of hypertriglyceridemic subjects.
Topics: Body Weight; Clofibrate; Humans; Hyperlipidemias; Lipoproteins, HDL; Phosphatidylcholine-Sterol O-Ac | 1978 |
Experimental porphyria induced by 3-(2,4,6-trimethylphenyl)-thioethyl)-4 methylsydnone.
Topics: Alcohol Oxidoreductases; Animals; Bile Ducts, Intrahepatic; Body Weight; Catalase; Chemical and Drug | 1975 |
Effect of clofibrate on cholesterol and DNA synthesis in rat ventral prostate.
Topics: Animals; Body Weight; Castration; Cholesterol; Clofibrate; Depression, Chemical; DNA; Liver; Male; O | 1979 |
Hyperlipoproteinemia induced by a transplantable pituitary tumor in the rat.
Topics: Animals; Body Weight; Cholesterol; Clofibrate; Electrophoresis, Agar Gel; Electrophoresis, Polyacryl | 1979 |
Effect of clofibrate and gemfibrozil on the activities of mitochondrial carnitine acyltransferases in rat liver. Dose--response relations.
Topics: Acyltransferases; Animals; Body Weight; Carnitine Acyltransferases; Clofibrate; Dose-Response Relati | 1979 |
Action of tiadenol and clofibrate on biliary excretions of cholesterol and bile salts in rats.
Topics: Animals; Bile; Bile Acids and Salts; Body Weight; Cholesterol; Clofibrate; Fatty Alcohols; Hypolipid | 1979 |
The effect of clofibrate on heart and plasma lipids in rats fed a diet containing rapeseed oil.
Topics: Animals; Arachis; Body Weight; Brassica; Clofibrate; Dietary Fats; Fatty Acids; Lipid Metabolism; Li | 1979 |
Bile formation and biliary lipid composition under the influence of clofibrate and phenobarbital pretreatment in the rat.
Topics: Animals; Bile; Bile Acids and Salts; Body Weight; Cholesterol; Clofibrate; Lipid Metabolism; Liver; | 1979 |
Treatment of hyperlipoproteinemia type II with etofibrate.
Topics: Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Glucose Tolerance Test; Humans; Hyperlipoprote | 1979 |
Effect of clofibrate administration on metabolic changes in the starving rat.
Topics: Animals; Body Weight; Clofibrate; Liver; Male; Organ Size; Rats; Starvation | 1979 |
Animal models for screening hypolipidemic agents. I. Response to clofibrate in NMRI-mice of different body-weights.
Topics: Animals; Body Weight; Clofibrate; Disease Models, Animal; Drug Evaluation, Preclinical; Hyperlipidem | 1978 |
Fundamental studies on physiological and pharmacological actions of L-ascorbate 2-sulfate. V. On the hypolipidemic and antiatherosclerotic effects of L-ascorbate 2-sulfate in rabbits.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Ascorbic Acid; Body Weight; Cholesterol; Clofibrate; Hyp | 1978 |
Maternal transport of chlorophenoxyisobutyrate at the foetal and neonatal stages of development.
Topics: Aging; Animals; Animals, Newborn; Body Weight; Clofibrate; Female; Fetus; In Vitro Techniques; Liver | 1978 |
Comparison of hypocholesterolemic activity for cyclic analogs of clofibrate in normolipemic rats.
Topics: Animals; Anticholesteremic Agents; Body Weight; Cholesterol; Clofibrate; Glucose Oxidase; Male; Micr | 1977 |
The effects of tiadenol, clofibrate and clofibride on bile composition in the rat.
Topics: Amides; Animals; Bile; Bile Acids and Salts; Body Weight; Cholesterol; Clofibrate; Fatty Alcohols; H | 1977 |
Hypocholesterolaemia in the rat after p-chlorophenoxyisobutyric acid (CPIB) administration as a synthetic triglyceride, 1,3-dipalmitoyl 2(p-chlorophenoxyisobutyroyl)-rac-glycerol.
Topics: Animals; Anticholesteremic Agents; Body Weight; Cholesterol; Clofibrate; Lipid Metabolism; Lipids; L | 1977 |
Differential increase of hepatic peroxisomal, mitochondrial and microsomal carnitine acyltransferases in clofibrate-fed rats.
Topics: Acyltransferases; Animals; Body Weight; Carnitine Acyltransferases; Centrifugation, Density Gradient | 1977 |
Pharmacokinetics of drugs in patients with the nephrotic syndrome.
Topics: Adult; Antipyrine; Blood Proteins; Body Weight; Clofibrate; Dose-Response Relationship, Drug; Female | 1975 |
Lack of effect of cholestyramine on the pharmacokinetics of clofibrate in man.
Topics: Adolescent; Adult; Aged; Bile; Body Weight; Cholestyramine Resin; Clofibrate; Drug Interactions; Fec | 1975 |
Effect of ascofuranone on serum lipids of rats fed a cholesterol rich diet.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Proteins; Body Weight; Cholesterol | 1975 |
Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia.
Topics: Animals; Body Weight; Butyrates; Cholesterol; Clofibrate; Dose-Response Relationship, Drug; Drug Eva | 1975 |
[Correction of endocrine-metabolic disorders in oncologic patients. The effect of biguanides (phenformin and adebita), miskleron and diphenin].
Topics: Adrenal Cortex Hormones; Aged; Biguanides; Blood Glucose; Body Weight; Breast Neoplasms; Buformin; C | 1975 |
[Letter: Treatment in hypercholestermia].
Topics: Adult; Body Weight; Clofibrate; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Smoking | 1976 |
The involvement of selenium in peroxisome proliferation caused by dietary administration of clofibrate to rats.
Topics: Animals; Body Weight; Cells, Cultured; Clofibrate; Diet; Glutathione Peroxidase; Glutathione Transfe | 1992 |
Involvement of calmodulin- and protein kinase C-related mechanism in an induction process of peroxisomal fatty acid oxidation-related enzymes by hypolipidemic peroxisome proliferators.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bezafibrate; Body Weight; Calmodulin; Catala | 1992 |
Effects of clofibrate on basal and insulin-activated glucose uptake in fast and slow skeletal muscles of rats.
Topics: Animals; Body Weight; Clofibrate; Glucose; Insulin; Male; Muscles; Organ Size; Rats; Rats, Inbred St | 1991 |
Effects of hypolipidemic drugs nafenopin and clofibrate on phenotypic expression and cell death (apoptosis) in altered foci of rat liver.
Topics: Animals; Body Weight; Carcinogens; Cell Survival; Clofibrate; Cyproterone; Cyproterone Acetate; Fema | 1990 |
Stereochemical selectivity in the induction of cytochrome P450IVA1 (P452)-dependent fatty acid hydroxylation and peroxisome proliferation.
Topics: Animals; Body Weight; Clofibrate; Cytochrome P-450 Enzyme System; Enzyme Induction; Fatty Acids; Hyd | 1991 |
Effect of simvastatin (MK-733) on plasma triacylglycerol levels in rats.
Topics: Adipose Tissue; Animals; Body Weight; Clofibrate; Energy Intake; Lipoprotein Lipase; Lipoproteins; L | 1991 |
Enhancement of NAD-linked isocitrate dehydrogenase activity in rat liver by clofibrate feeding.
Topics: Animals; Body Weight; Clofibrate; Diet; Isocitrate Dehydrogenase; Liver; Male; Mitochondria, Liver; | 1991 |
Atherosclerosis mouse model induced by a high-cholesterol diet supplemented with beta-aminopropionitrile: effects of various anti-atherosclerotic agents on the biochemical parameters.
Topics: 4-Aminobenzoic Acid; Aminopropionitrile; Animals; Aorta; Arteriosclerosis; Body Weight; Cholesterol; | 1990 |
Promoting effect of the peroxisome proliferator, clofibrate, but not di(2-ethylhexyl)phthalate, on urinary bladder carcinogenesis in F344 rats initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Topics: Animals; Body Weight; Butylhydroxybutylnitrosamine; Carcinogens; Clofibrate; Diethylhexyl Phthalate; | 1990 |
Toxicological studies on a benzofurane derivative. II. Demonstration of peroxisome proliferation in rat liver.
Topics: Animals; Benzbromarone; Body Weight; Clofibrate; Liver; Male; Microbodies; Microscopy, Electron; Org | 1990 |
Induction of peroxisome proliferation in rainbow trout exposed to ciprofibrate.
Topics: Acyl-CoA Oxidase; Analysis of Variance; Animals; Blotting, Western; Body Weight; Catalase; Clofibrat | 1990 |
Effect of the peroxisome proliferator ciprofibrate on hepatic DNA synthesis and hepatic composition following partial hepatectomy in rats.
Topics: Administration, Oral; Animals; Body Weight; Clofibrate; Clofibric Acid; DNA; Female; Fibric Acids; H | 1990 |
Characterization of the hepatic responses to the short-term administration of ciprofibrate in several rat strain. Co-induction of microsomal cytochrome P-450 IVA1 and peroxisome proliferation.
Topics: Administration, Oral; Animals; Body Weight; Cell Division; Clofibrate; Clofibric Acid; Cytochrome P- | 1990 |
In vivo and in vitro peroxisome proliferation properties of selected clofibrate analogues in the rat. Structure-activity relationships.
Topics: 2-Methyl-4-chlorophenoxyacetic Acid; Acyl-CoA Oxidase; Animals; Body Weight; Cell Division; Choleste | 1990 |
Comparison of dehydroepiandrosterone and clofibric acid treatments in obese Zucker rats.
Topics: Animals; Blood Glucose; Body Weight; Clofibrate; Clofibric Acid; Dehydroepiandrosterone; Disease Mod | 1989 |
Modulation of diethylnitrosamine-initiated placental glutathione S-transferase positive preneoplastic and neoplastic lesions by clofibrate, a hepatic peroxisome proliferator.
Topics: Animals; Body Weight; Clofibrate; Diethylnitrosamine; Female; Glutathione Transferase; Immunoenzyme | 1989 |
Teratological study of the hypolipidaemic drugs etofylline clofibrate (VULM) and fenofibrate in Swiss mice.
Topics: Animals; Body Weight; Clofibrate; Female; Fenofibrate; Fetus; Gestational Age; Hypolipidemic Agents; | 1989 |
Hepatic foci of cellular and enzymatic alteration and nodules in rats treated with clofibrate or diethylnitrosamine followed by phenobarbital: their rate of onset and their reversibility.
Topics: Animals; Body Weight; Clofibrate; Diethylnitrosamine; gamma-Glutamyltransferase; Glucosephosphate De | 1986 |
Differential induction profile of drug-metabolizing enzymes after treatment with hypolipidaemic agents.
Topics: Animals; Biphenyl Compounds; Body Weight; Butyrophenones; Clofibrate; Clofibric Acid; Cytochrome P-4 | 1987 |
The effect of feeding fish oils, vegetable oils and clofibrate on the ketogenesis from long chain fatty acids in hepatocytes.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Body Weight; Carbon Radioisotopes; Clofibrate; Fatty A | 1986 |
Epoxide-metabolizing enzymes in mammary gland and liver from BALB/c mice and effects of inducers on enzyme activity.
Topics: Animals; Body Weight; Chromatography, Affinity; Clofibrate; Enzyme Induction; Enzyme-Linked Immunoso | 1988 |
Peroxisomal beta-oxidation and catalase activities in fetal rat liver: effect of maternal treatment with clofibrate.
Topics: Animals; Body Weight; Catalase; Clofibrate; Female; Liver; Maternal-Fetal Exchange; Microbodies; Org | 1988 |
Hypocholesterolemic activity of racemic dichlorophenoxypropionic acid or its enantiomers in rats.
Topics: 2,4-Dichlorophenoxyacetic Acid; Animals; Anticholesteremic Agents; Body Weight; Cholesterol; Clofibr | 1987 |
Effect of pollen extract on the development of experimental atherosclerosis in rabbits.
Topics: Animals; Arteriosclerosis; Body Weight; Cholesterol, Dietary; Cholesterol, HDL; Clofibrate; Diet, At | 1986 |
The effect of three hypolipidemic drugs on catalase activity and peroxisomal and mitochondrial palmitate oxidation in rat cardiac and skeletal muscle.
Topics: Animals; Body Weight; Catalase; Clofibrate; Clofibric Acid; Fibric Acids; Hypolipidemic Agents; Male | 1986 |
Effect of clofibrate and colestipol singly and in combination on plasma lipids and lipoproteins in type III hyperlipoproteinemia.
Topics: Adult; Body Weight; Cholesterol; Clofibrate; Colestipol; Drug Therapy, Combination; Humans; Hyperlip | 1985 |
Metabolic relationships among the plasma lipoproteins. Reciprocal changes in the concentrations of very low and low density lipoproteins in man.
Topics: Adolescent; Adult; Angina Pectoris; Body Weight; Cholesterol; Clofibrate; Coronary Disease; Female; | 1972 |
Pharmacological study of hydroxy bis-[2-(p-chlorophenoxy)-isobutyric acid] aluminium. II. The effect of hydroxy bis-[2-(-chlorophenoxy)-isobutyric acid] aluminum on lipid metabolism in hypercholesterolimic rats.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Body Weight; Brain; Cholesterol; Cholesterol, Die | 1973 |
Hyperlipoproteinemia. Some basic concepts on diagnosis and management.
Topics: Adult; Age Factors; Aged; Aminosalicylic Acids; Blood Protein Disorders; Body Weight; Cholesterol; C | 1973 |
A kinetic comparison of the physiological effects of clofibrate and clofenapate in the rat.
Topics: Animals; Body Weight; Butyrates; Catalase; Cell Nucleus; Cholesterol; Clofenapate; Clofibrate; Depre | 1974 |
[Lipid depression by etofibrate in a comparative study in rats with artificial hyperlipidemia].
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Body Weight; Cholesterol; Clofibrate; Depressio | 1974 |
Pharmacological study of hydroxy bis-[2-(p-chlorophenoxy)-isobutyric acid] aluminium. I. The effect of hydroxy bis-[2-(p-chlorophenoxy)-isobutyric acid] aluminum on lipid metabolism in normal rats.
Topics: Aluminum; Animals; Anticholesteremic Agents; Body Weight; Butyrates; Cholesterol; Clofibrate; Fatty | 1973 |
Studies of primary hyperlipoproteinemias. IV. Treatment.
Topics: Adult; Blood Protein Disorders; Body Weight; Cholesterol; Clofibrate; Diet Therapy; Humans; Lipoprot | 1972 |
[Clinical and epidemiological aspects of human glyceridemia. IV. Etiological diagnosis and treatment of hyperglyceridemia. Practical aspects].
Topics: Alcohol Drinking; Body Weight; Clofibrate; Diet; Dietary Carbohydrates; Electrophoresis, Starch Gel; | 1972 |
Growth hormone secretion in primary endogenous hypertriglyceridemia.
Topics: Adult; Arginine; Blood Glucose; Body Weight; Clofibrate; Fatty Acids, Nonesterified; Female; Glucago | 1973 |
[Does magnesium-orotate improve the effect of lipid lowering drugs?].
Topics: Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Body Weight; Cholesterol; Clofibra | 1973 |
The effects of colestipol resin and of colestipol plus clofibrate on the turnover of plasma cholesterol in man.
Topics: Adult; Anticholesteremic Agents; Body Weight; Carbon Isotopes; Cholesterol; Clofibrate; Drug Synergi | 1973 |
Effect of SaH 42-348, an analog of clofibrate, on lipid metabolism in rats.
Topics: Animals; Anticholesteremic Agents; Body Weight; Cholesterol; Cholesterol, Dietary; Clofibrate; Diet, | 1973 |
Editorial: Diet and drugs for hyperlipidaemia.
Topics: Body Height; Body Weight; Clofibrate; Diet; Humans; Hyperlipidemias; Patient Care Planning; Vascular | 1973 |
[Hyperlipoproteinemia type 3. Report on 5 cases].
Topics: Adult; Blood Protein Electrophoresis; Body Weight; Cholesterol; Clofibrate; Diagnosis, Differential; | 1973 |
The effect of ethyl-alpha-p-chlorophenoxisobutyrate (clofibrate) on alcohol metabolism.
Topics: Administration, Oral; Alcohol Oxidoreductases; Animals; Body Weight; Carbon Radioisotopes; Catalase; | 1973 |
Treatment of type II and type IV Fredrickson's hyperlipoproteinemia.
Topics: Adolescent; Adult; Alcohol Drinking; Body Weight; Child; Cholesterol, Dietary; Cholestyramine Resin; | 1973 |
Potential hypolipidemic agents. 7. Synthesis and lipid-lowering properties of 2-(dibenzofuranyloxy)-2-methylpropionates and related compounds.
Topics: Animals; Benzofurans; Body Weight; Butyrates; Cholesterol; Clofibrate; Hypolipidemic Agents; Male; M | 1974 |
Differential effects of benzodioxane, chroman, and dihydrobenzofuran analogs of clofibrate on various parameters of hepatic drug metabolism.
Topics: Aniline Compounds; Animals; Benzofurans; Benzopyrans; Body Weight; Clofibrate; Cytochrome P-450 Enzy | 1974 |
Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia.
Topics: Adult; Aged; Antigens; Blood Glucose; Blood Protein Disorders; Body Weight; Clofibrate; Fatty Acids, | 1974 |
Structure of hepatic microbodies in rats treated with acetylsalicylic acid, clofibrate, and dimethrin.
Topics: Animals; Aspirin; Benzyl Compounds; Body Weight; Carboxylic Acids; Cholesterol; Chrysanthemum cinera | 1974 |
Potential hypolipidemic agents. IX. Heterocyclic compouns related to methyl clofenapate.
Topics: Animals; Appetite; Body Weight; Chemical Phenomena; Chemistry; Cholesterol; Clofibrate; Depression, | 1974 |
Potential hypolipidemic agents. 8. 2-Chloro-5-piperidinosulphono-3-thiophenecarboxylic acids.
Topics: Animals; Body Weight; Carboxylic Acids; Cholesterol; Clofibrate; Depression, Chemical; Drug Evaluati | 1974 |
Restraint of cholesterol accumulation in tissue pools associated with drastic short-term lowering of serum cholesterol levels by clofibrate or cholestyramine in hypercholesterolemic swine.
Topics: Animals; Bile Acids and Salts; Body Weight; Carbon Radioisotopes; Cholesterol; Cholesterol, Dietary; | 1974 |
Long-term treatment of hyperlipidemic patients with clofibrate.
Topics: Adult; Aged; Body Weight; Cholesterol; Clofibrate; Female; Glucose; Glucose Tolerance Test; Humans; | 1971 |
[Classification of hyperlipoproteinaemia in primary gout].
Topics: Adult; Aged; Arteriosclerosis; Blood Protein Disorders; Body Weight; Carbohydrate Metabolism; Clofib | 1972 |
Serum lipid precursors of coronary heart disease.
Topics: Adult; Aged; Arteriosclerosis; Blood Protein Disorders; Body Weight; Cholesterol; Cholestyramine Res | 1971 |
Influence of obesity on the relationship between insulin and triglyceride levels in endogenous hypertriglyceridemia.
Topics: Adult; Blood Glucose; Body Weight; Clofibrate; Dietary Carbohydrates; Fatty Acids, Nonesterified; Gl | 1971 |
Induced alterations in composition of bile of persons having cholelithiasis.
Topics: Bile; Bile Acids and Salts; Body Weight; Cholecystokinin; Cholelithiasis; Cholesterol; Cholestyramin | 1971 |
Treatment of familial hypercholesterolemia in children.
Topics: Adolescent; Arteriosclerosis; Body Weight; Child; Child, Preschool; Cholesterol; Clofibrate; Diet Th | 1971 |
[Antilipidemic agents].
Topics: Adult; Alcohols; Anticholesteremic Agents; Biguanides; Blood Protein Disorders; Body Weight; Cholest | 1971 |
A long-time study of the blood lipids of two students of atherosclerosis.
Topics: Age Factors; Aged; Arteriosclerosis; Body Weight; Cholesterol; Clofibrate; Coronary Disease; Diet; D | 1969 |
Lipid lowering influence of ethyl p-chlorophenoxyisobutyrate in liver of rats fed high fat diets.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Body Weight; Cholesterol; Clofibrate; Depre | 1970 |
Treatment of the hyperlipidemic states with special emphasis on the place of cholestyramine in therapy.
Topics: Adolescent; Adult; Aged; Body Weight; Child; Cholesterol; Cholestyramine Resin; Clofibrate; Dextroth | 1970 |
Effect of atromid-S and high fat diet on lipid contents and lipolysis in rat tissues and serum.
Topics: Anticholesteremic Agents; Body Weight; Cholesterol; Clofibrate; Dietary Fats; Hypercholesterolemia; | 1971 |
Ultracentrifugal demonstration of floating beta lipoproteins in type 3 hyperlipoproteinemia. Diagnostic value.
Topics: Angina Pectoris; Blood Protein Disorders; Blood Protein Electrophoresis; Body Weight; Cholesterol; C | 1971 |
Diet and drug therapy for hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Body Weight; Cholestyramine Resin; Clofibrate; Diet Therapy; Dietary Carbo | 1971 |